Skip to main content

Eli Lilly vs Merck: Strategic Comparison

Direct Answer

Eli Lilly and Merck reported almost identical total revenue in 2025, $65.179 billion for Lilly against $65.011 billion for Merck, but Lilly is pulling ahead fast: its tirzepatide drugs Mounjaro and Zepbound pushed second-quarter 2026 revenue up 48% to $23.0 billion, while Merck's Q2 2026 sales grew just 5% to $16.6 billion. Lilly is also more profitable, with 2025 net income of $20.640 billion versus Merck's $18.254 billion, and far more valuable, with a market capitalization near $1.03 trillion in late September 2026 compared with Merck's roughly $368 billion. On balance, Lilly is the bigger and faster-growing company overall, even though their current-year revenue is close to a tie.

In the first quarter of 2026, Eli Lilly's diabetes and obesity drug Mounjaro posted $8.7 billion in global sales, overtaking Merck's cancer immunotherapy Keytruda at $7.9 billion as the world's best-selling drug brand, a reversal that captures where these two drugmakers are headed. Lilly, founded in Indianapolis in 1876 by Colonel Eli Lilly, reported $65.179 billion in 2025 revenue and $20.640 billion in net income, led by Chair and CEO David A. Ricks since January 2017. Merck & Co., founded in 1891 in New York as the U.S. arm of Germany's E. Merck and now based in Rahway, New Jersey, reported $65.011 billion in 2025 sales and $18.254 billion in net income attributable to the company, led by Chairman and CEO Robert M. Davis since July 1, 2021. Lilly employed about 50,000 people at the end of 2025 against Merck's roughly 75,000, and Lilly's 48% second-quarter 2026 revenue growth dwarfed Merck's 5%.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldEli Lilly and CompanyMerck & Co., Inc.
Latest annual revenue$65.2B (FY2025)$65.0B (FY2025)
Founded18761891
Employees50,00075,000
Market Cap$1.06T$368.3B
HeadquartersUnited StatesUnited States
Revenue / Employee$1.30M / employee$867k / employee
Valuation Multiple16.3x P/S5.7x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

Eli Lilly and Company Strategic Vector

FY2025 Revenue Baseline

Eli Lilly's corporate strategy focuses on expanding manufacturing capacity to meet soaring global demand for incretin therapeutics while advancing a diversified next-generation biopharmaceutical pipeline. Under Chief Executive Officer David Ricks, Lilly committed more than eighteen billion dollars to construct and expand state-of-the-art sterile injectable manufacturing campuses in Indiana, North Carolina, Ireland, and Germany to alleviate supply bottlenecks for Mounjaro and Zepbound. Concurrently, the company is pioneering oral, small-molecule GLP-1 receptor agonists (orforglipron) to provide convenient pill alternatives to weekly injections, alongside triple-hormone agonists (retatrutide) targeting GIP, GLP-1, and glucagon receptors for profound metabolic intervention. In neuroscience, the regulatory approval of Kisunla (donanemab) positions Lilly at the forefront of amyloid-clearing Alzheimer's therapies, creating another long-duration therapeutic franchise.

Productivity: $1.30M / employee

Merck & Co., Inc. Strategic Vector

FY2025 Revenue Baseline

Merck's corporate strategy focuses on maximizing Keytruda's clinical utility through subcutaneous delivery formulations while diversifying its post-2028 patent expiration pipeline through targeted oncology and cardiometabolic acquisitions. Led by Chief Executive Officer Robert Davis, Merck is developing a subcutaneous formulation of pembrolizumab combined with berahyaluronidase alfa, which could extend patent protection and shift patients from lengthy intravenous hospital infusions to convenient clinic injections. To expand beyond Keytruda, Merck acquired Prometheus Biosciences for nearly eleven billion dollars (adding MK-7240 for ulcerative colitis and Crohn's disease), Acceleron Pharma (launching Winrevair/sotatercept for pulmonary arterial hypertension), and forged multi-billion-dollar antibody-drug conjugate partnerships with Daiichi Sankyo.

Productivity: $867k / employee
Comparative Divergence: Lilly and Merck are not traditional rivals - Lilly's growth comes from obesity and diabetes drugs while Merck's comes from oncology and vaccines - but 2026 put them in direct competition for the title of world's top-selling drug. Mounjaro's $8.7 billion in first-quarter 2026 global sales overtook Keytruda's $7.9 billion, and by the third quarter Lilly's combined tirzepatide sales of $24.8 billion year-to-date had widened the gap over Keytruda's $23.3 billion. Merck responded by launching subcutaneous Keytruda Qlex in September 2025 and expanding Keytruda into new cancer indications, while Lilly launched the oral GLP-1 pill Foundayo (orforglipron) in April 2026 to keep tirzepatide ahead of Novo Nordisk's semaglutide franchise.

Eli Lilly vs Merck Market Share

Eli Lilly and Company market share
Eli Lilly and Company is one of the premier market leaders in Pharmaceuticals, obesity medicines, diabetes care, oncology, immunology, and neuroscience, commanding substantial market share and strong brand equity across its core geographic operating regions.
Merck & Co., Inc. market share
Merck & Co., Inc. is one of the premier market leaders in Pharmaceuticals / Biotechnology / Animal Health, commanding substantial market share and strong brand equity across its core geographic operating regions.

Quick Stats Comparison

MetricEli Lilly and CompanyMerck & Co., Inc.
Revenue$65.2B (FY2025)$65.0B (FY2025)
Founded18761891
HeadquartersIndianapolis, IndianaRahway, New Jersey
Market Cap$1.06T$368.3B
Employees50,00075,000
Revenue / Employee$1.30M / employee$867k / employee
Valuation Multiple16.3x P/S5.7x P/S

Eli Lilly Revenue vs Merck Revenue — Year by Year

YearEli Lilly and CompanyMerck & Co., Inc.Higher reported revenue
2025$65.2B$65.0BEli Lilly and Company (approx. USD)
2024$45.0B$64.2BMerck & Co., Inc. (approx. USD)
2023$34.1B$60.1BMerck & Co., Inc. (approx. USD)
2022$28.5B$59.3BMerck & Co., Inc. (approx. USD)
2021$28.3B$48.7BMerck & Co., Inc. (approx. USD)

Business Model Breakdown

Overview: Eli Lilly and Company vs Merck & Co., Inc.

This in-depth comparison examines Eli Lilly and Company and Merck & Co., Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Merck & Co., Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Merck & Co., Inc. is widest.

On the headline numbers, annual revenue is $65.2B (FY2025) for Eli Lilly and Company and $65.0B (FY2025) for Merck & Co., Inc., while their respective market capitalizations stand at $1.06T and $368.3B. Both Eli Lilly and Company and Merck & Co., Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

Eli Lilly and Company: Eli Lilly is a 150-year-old Indianapolis pharmaceutical company that has become the world's largest drugmaker by market value. For most of its history it was best known for insulin and Prozac. Since 2022, tirzepatide, a dual GIP/GLP-1 agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, has transformed its scale, taking revenue from $28.5 billion in 2022 to $65.2 billion in 2025 and a guided $85-87 billion in 2026. The company is headquartered in Indianapolis, Indiana.

Merck & Co., Inc.: Merck & Co. is one of the largest U.S. pharmaceutical companies by sales, with $65.0 billion in 2025 revenue, about 75,000 employees and a market value near $368 billion in late September 2026. It researches, makes and sells cancer drugs, vaccines, cardiovascular and infectious-disease medicines, and animal health products in more than 140 markets. Keytruda, its PD-1 cancer immunotherapy, was the world's top-selling drug brand in 2025 and drives about half of company sales, so the company's current agenda centers on replacing that revenue before U.S. patent protection begins to lapse in 2028. The company is headquartered in Rahway, New Jersey.

Business Models: How Eli Lilly and Company and Merck & Co., Inc. Make Money

Eli Lilly and Company and Merck & Co., Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Merck & Co., Inc..

Eli Lilly and Company business model: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience. The company's business model is powered by targeted biologic therapies and synthetic peptide chemistry, generating revenue through patent-protected prescription drug sales to pharmaceutical wholesalers, hospital systems, and pharmacy benefit managers. Eli Lilly's revenue flywheel is led by its dual GIP/GLP-1 receptor agonist franchise—tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Beyond metabolic health, the company derives substantial recurring cash flows from oncology (Verzenio for HR+/HER2- breast cancer), immunology (Taltz, Omvoh), and neuroscience (Kisunla/donanemab for early symptomatic Alzheimer's disease). Revenue is reinvested at industry-leading rates into clinical trials, automated fill-finish manufacturing plants, and novel drug delivery platforms.

Merck & Co., Inc. business model: Merck & Co., Inc. (known as MSD outside the United States and Canada) is an innovation-led global biopharmaceutical company that discovers, develops, and delivers prescription medicines, vaccines, biologic therapies, and animal health products. The company's business model is divided into two reporting segments: Pharmaceutical and Animal Health. The Pharmaceutical division generates the vast majority of revenue, anchored by the world's leading immuno-oncology biologic, Keytruda (pembrolizumab)—a humanized monoclonal antibody that blocks the PD-1 pathway to treat dozens of cancer indications. Additional pharmaceutical pillars include human papillomavirus (HPV) vaccines (Gardasil/Gardasil 9), cardiovascular therapies, and infectious disease treatments. The Animal Health division discovers and markets veterinary pharmaceuticals, vaccines, and health management software for livestock and companion animals.

Competitive Advantage: Eli Lilly and Company vs Merck & Co., Inc.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Merck & Co., Inc..

Eli Lilly and Company competitive advantage: Eli Lilly's formidable economic moat is founded on its multi-decade dominance in peptide synthesis, patent-protected intellectual property, and extensive global sterile manufacturing infrastructure. The development of tirzepatide established a first-in-class multi-receptor incretin platform that demonstrated superior glycemic control and weight reduction compared to single-hormone alternatives, granting Eli Lilly formidable pricing power and formulary tier positioning across private and public health insurance programs. Developing complex biologic therapies requires specialized high-speed parenterals, automated aseptic syringe filling lines, and rigorous peptide purification facilities that represent multi-billion-dollar barriers to entry. Lilly's patent portfolio creates statutory commercial exclusivity lasting through the next decade, while its clinical development velocity consistently brings breakthrough molecular entities from early discovery to regulatory approval ahead of historical pharmaceutical timelines.

Merck & Co., Inc. competitive advantage: Merck's insurmountable competitive moat is built upon Keytruda's extraordinary clinical efficacy across dozens of tumor types, its entrenched standard-of-care position in first-line non-small cell lung cancer, and Gardasil's global dominance in preventative oncology. Keytruda is the highest-grossing pharmaceutical drug in the world, approved for more than forty distinct cancer indications across multiple stages of disease. This extensive label breadth creates high switching barriers for oncologists, who rely on Keytruda as the foundational backbone for combination cancer therapies. In vaccines, Gardasil operates with near-monopolistic scale in cervical cancer prevention, supported by national public health immunization mandates and complex multi-valent recombinant virus-like particle (VLP) manufacturing processes that prevent biosimilar competition.

Growth Strategy: Where Eli Lilly and Company and Merck & Co., Inc. Are Headed

Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Merck & Co., Inc. each plan to expand from here.

Eli Lilly and Company growth strategy: Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3. Lilly continues to build U.S. and European manufacturing capacity and uses acquisitions to add pipeline assets.

Merck & Co., Inc. growth strategy: Merck's strategy is to use Keytruda cash flow to build a broader portfolio before 2028. It moved patients toward subcutaneous Keytruda Qlex (FDA-approved September 19, 2025), expanded Keytruda into earlier-stage cancers, and bought late-stage or commercial assets: Verona Pharma for about $10 billion (completed October 2025, adding COPD drug Ohtuvayre), Cidara Therapeutics for about $9.2 billion (completed January 2026, adding influenza preventive CD388), and Terns Pharmaceuticals for about $6.7 billion (completed in Q2 2026, adding CML candidate MK-4208). Earlier deals include Acceleron ($11.5 billion, 2021), Prometheus Biosciences ($10.8 billion, 2023) and the Daiichi Sankyo ADC collaboration (up to $22 billion, 2023).

Financial Picture: Eli Lilly and Company vs Merck & Co., Inc.

A closer look at the financial trajectory of Eli Lilly and Company and Merck & Co., Inc. rounds out the comparison.

Eli Lilly and Company: Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.

Merck & Co., Inc.: Merck reported $65.0 billion in 2025 sales, up 1% from $64.2 billion in 2024, and $18.3 billion in net income attributable to Merck. Keytruda/Keytruda Qlex grew 7% to $31.7 billion, offsetting a 39% Gardasil decline. Momentum continued in 2026: Q2 2026 sales rose 5% to $16.6 billion, with Keytruda at $8.4 billion (including $463 million from Keytruda Qlex), Winrevair up 75% to $588 million and Animal Health up 8% to $1.8 billion. A $2.31-per-share charge for the Terns acquisition produced a Q2 GAAP net loss of $1.3 billion. In August 2026 Merck raised its full-year 2026 sales outlook to $66.3 billion to $67.3 billion, with non-GAAP EPS of $2.66 to $2.76 after Terns-related charges. Merck & Co. commands a robust market valuation frequently over $300 billion, driven heavily by its blockbuster oncology drug Keytruda.

Company-Specific SWOT Notes

Eli Lilly and Company

Strength

Lilly's tirzepatide franchise represents one of the most commercially successful pharmaceutical launches in history, with combined Mounjaro and Zepbound revenues of $36.5 billion in fiscal year 2025 and significant additional indication expansion in developmen

Strength

With more than 50 active molecules in clinical development and $13.3 billion invested in R&D in fiscal year 2025, Lilly's pipeline represents one of the most productive in the pharmaceutical industry.

Weakness

Despite a multi-billion-dollar manufacturing expansion program, Lilly's production capacity for tirzepatide and other injectable biologics has lagged the notable demand generated by commercial launches, resulting in drug shortages that have frustrated patients

Weakness

Tirzepatide, sold as Mounjaro and Zepbound, produced about 56% of Lilly's 2025 revenue and roughly 65% of Q2 2026 revenue.

Opportunity

The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the first small-molecule GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions.

Threat

The Inflation Reduction Act's Medicare drug price negotiation program, which allows the Centers for Medicare and Medicaid Services to directly negotiate prices for high-expenditure drugs, represents a structural threat to Lilly's revenue model in the United St

Merck & Co., Inc.

Strength

Keytruda's approval across more than 40 cancer indications and its more than 1,600 active clinical trials create a clinical evidence base and physician relationship network that represents the most strong competitive position in the pharmaceutical industry tod

Strength

Merck reported $65.0 billion in 2025 sales and $18.3 billion in net income attributable to Merck, and Animal Health grew 8% to $1.8 billion in Q2 2026.

Weakness

Keytruda's US$31.7 billion in fiscal year 2025 sales represents roughly 49 percent of total company sales, a level of product concentration that creates a structurally fragile financial profile when that product faces patent-driven competitive disruption in 20

Weakness

Gardasil sales fell 39% to $5.2 billion in 2025 after demand in China collapsed, showing how one government's procurement decisions can move billions in revenue.

Opportunity

Subcutaneous pembrolizumab (Keytruda Qlex, FDA-approved on September 19, 2025), a formulation allowing injection in approximately five minutes versus 30-minute intravenous administration, could substantially reduce the commercial attractiveness of biosimilar I

Threat

The Inflation Reduction Act's Medicare drug price negotiation framework represents the most significant structural threat to Merck's near-term financial profile.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScaleEli Lilly and Company$65.2B (FY2025) versus $65.0B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierEli Lilly and CompanyEli Lilly and Company was founded in 1876; Merck & Co., Inc. was founded in 1891.
Verdict

Comparison Takeaway: Eli Lilly vs Merck

These two drugmakers are moving in opposite directions. Lilly's obesity and diabetes franchise is compounding: Mounjaro and Zepbound combined for $36.5 billion of 2025 revenue, about 65% of Lilly's Q2 2026 sales, and Lilly's operating margin, near 47% in 2026, is more than double Merck's roughly 19.7%. Merck's revenue leans on one aging asset: Keytruda supplied about 49% of 2025 sales but its U.S. patent protection starts expiring in 2028, and Merck spent roughly $26 billion between October 2025 and mid-2026 buying Verona Pharma, Cidara Therapeutics and Terns Pharmaceuticals to find replacement revenue, charges from which pushed Merck to a $1.3 billion GAAP net loss in the second quarter of 2026. Merck trades far cheaper, around 15 times earnings, against a markedly higher multiple for Lilly, reflecting the market's view that Lilly's growth is more durable. For anyone choosing between them, Lilly is the growth story and Merck is the value-and-income story with a visible 2028 patent cliff.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: Eli Lilly vs Merck

Is Eli Lilly bigger than Merck?

By 2025 revenue the two are nearly tied: Lilly reported $65.179 billion against Merck's $65.011 billion. But Lilly is bigger by market value, worth about $1.03 trillion in late September 2026 versus Merck's roughly $368 billion, and grew revenue 48% in the second quarter of 2026 compared with Merck's 5%.

Which is more profitable, Eli Lilly or Merck?

Eli Lilly is more profitable. It reported $20.640 billion of net income in 2025 against Merck's $18.254 billion, and Lilly's operating margin was near 47% in 2026 versus roughly 19.7% at Merck, which also took a $1.3 billion GAAP net loss in the second quarter of 2026 from acquisition charges.

Who are the CEOs of Eli Lilly and Merck?

David A. Ricks has been Eli Lilly's Chair and CEO since January 2017. Robert M. Davis has been Merck's CEO since July 1, 2021 and added the chairman title on December 1, 2022, succeeding Kenneth C. Frazier in both roles.

Did Mounjaro really overtake Keytruda in sales?

Yes. Eli Lilly's Mounjaro generated $8.7 billion in first-quarter 2026 global sales, passing Merck's Keytruda at $7.9 billion, and by the third quarter Lilly's combined Mounjaro-and-Zepbound tirzepatide sales reached $24.8 billion year-to-date against Keytruda's $23.3 billion.

Which is the better stock, Eli Lilly or Merck?

It depends on the goal. Eli Lilly is the growth pick, guiding to $85-87 billion of 2026 revenue, about 30% growth, on Mounjaro, Zepbound and Foundayo demand, while Merck is the value-and-income pick, trading near 15 times earnings but facing a 2028 patent cliff when Keytruda's U.S. exclusivity begins to lapse.

Which company was founded first, Eli Lilly and Company or Merck & Co., Inc.?

Eli Lilly and Company was founded in 1876; Merck & Co., Inc. was founded in 1891.

What revenue did Eli Lilly and Company and Merck & Co., Inc. report?

Eli Lilly and Company had $65.2B (FY2025), while Merck & Co., Inc. had $65.0B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do Eli Lilly and Company and Merck & Co., Inc. make money?

Eli Lilly and Company: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience. Merck & Co., Inc.: Merck & Co., Inc. (known as MSD outside the United States and Canada) is an innovation-led global biopharmaceutical company that discovers, develops, and delivers prescription medicines, vaccines, biologic therapies, and animal health products.

Which is better, Eli Lilly and Company or Merck & Co., Inc.?

There is no evidence-based single winner. Compare Eli Lilly and Company and Merck & Co., Inc. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

Eli Lilly and Merck reported almost identical total revenue in 2025, $65.179 billion for Lilly against $65.011 billion for Merck, but Lilly is pulling ahead fast: its tirzepatide drugs Mounjaro and Zepbound pushed second-quarter 2026 revenue up 48% to $23.0 billion, while Merck's Q2 2026 sales grew just 5% to $16.6 billion. Lilly is also more profitable, with 2025 net income of $20.640 billion versus Merck's $18.254 billion, and far more valuable, with a market capitalization near $1.03 trillion in late September 2026 compared with Merck's roughly $368 billion. On balance, Lilly is the bigger and faster-growing company overall, even though their current-year revenue is close to a tie.

Verdict

These two drugmakers are moving in opposite directions. Lilly's obesity and diabetes franchise is compounding: Mounjaro and Zepbound combined for $36.5 billion of 2025 revenue, about 65% of Lilly's Q2 2026 sales, and Lilly's operating margin, near 47% in 2026, is more than double Merck's roughly 19.7%. Merck's revenue leans on one aging asset: Keytruda supplied about 49% of 2025 sales but its U.S. patent protection starts expiring in 2028, and Merck spent roughly $26 billion between October 2025 and mid-2026 buying Verona Pharma, Cidara Therapeutics and Terns Pharmaceuticals to find replacement revenue, charges from which pushed Merck to a $1.3 billion GAAP net loss in the second quarter of 2026. Merck trades far cheaper, around 15 times earnings, against a markedly higher multiple for Lilly, reflecting the market's view that Lilly's growth is more durable. For anyone choosing between them, Lilly is the growth story and Merck is the value-and-income story with a visible 2028 patent cliff.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). Eli Lilly and Company vs Merck & Co., Inc. Comparison. from https://corpdigest.com/compare/eli-lilly-vs-merck

MLA Format

CorpDigest. "Eli Lilly and Company vs Merck & Co., Inc. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/eli-lilly-vs-merck.

Chicago Format

CorpDigest. "Eli Lilly and Company vs Merck & Co., Inc. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/eli-lilly-vs-merck.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.